Last reviewed · How we verify
Non-Hyperkeratotic Actinic Keratoses
Approved treatments
- Levulan · Sun Pharma
Levulan accumulates in abnormal skin cells, allowing for visualization and treatment. - Ameluz · Sherrif Ibrahim
- Gliolan · Abramson Cancer Center at Penn Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-Hyperkeratotic Actinic Keratoses patent landscape — cliff calendar, originator estates, attackable patents
- Non-Hyperkeratotic Actinic Keratoses treatment landscape brief
- Non-Hyperkeratotic Actinic Keratoses treatment updates RSS
Frequently asked questions about Non-Hyperkeratotic Actinic Keratoses
What drugs treat Non-Hyperkeratotic Actinic Keratoses?
Tracked treatments include Levulan, Ameluz, Gliolan.
What is the treatment for Non-Hyperkeratotic Actinic Keratoses?
Standard treatment for Non-Hyperkeratotic Actinic Keratoses includes Levulan, Ameluz, Gliolan. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-Hyperkeratotic Actinic Keratoses patent cliff · Non-Hyperkeratotic Actinic Keratoses CI report
- Treatment: Levulan · Sun Pharma
- Treatment: Ameluz · Sherrif Ibrahim
- Treatment: Gliolan · Abramson Cancer Center at Penn Medicine
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing